Cambridge Investment Research Advisors Inc. Takes Position in Dynavax Technologies Corporation (NASDAQ:DVAX)

Cambridge Investment Research Advisors Inc. bought a new stake in Dynavax Technologies Corporation (NASDAQ:DVAX - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 24,044 shares of the biopharmaceutical company's stock, valued at approximately $312,000.

A number of other institutional investors have also added to or reduced their stakes in DVAX. Deep Track Capital LP raised its holdings in Dynavax Technologies by 42.0% during the 4th quarter. Deep Track Capital LP now owns 17,791,486 shares of the biopharmaceutical company's stock valued at $227,197,000 after buying an additional 5,265,000 shares during the last quarter. Deerfield Management Company L.P. Series C grew its stake in shares of Dynavax Technologies by 23,990.1% in the fourth quarter. Deerfield Management Company L.P. Series C now owns 5,193,823 shares of the biopharmaceutical company's stock worth $66,325,000 after purchasing an additional 5,172,263 shares during the last quarter. Norges Bank bought a new stake in shares of Dynavax Technologies in the fourth quarter worth about $7,762,000. D. E. Shaw & Co. Inc. grew its stake in shares of Dynavax Technologies by 34.0% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,918,340 shares of the biopharmaceutical company's stock worth $24,497,000 after purchasing an additional 486,981 shares during the last quarter. Finally, WINTON GROUP Ltd grew its stake in shares of Dynavax Technologies by 339.0% in the fourth quarter. WINTON GROUP Ltd now owns 426,814 shares of the biopharmaceutical company's stock worth $5,450,000 after purchasing an additional 329,579 shares during the last quarter. Institutional investors own 96.96% of the company's stock.

Analyst Ratings Changes

DVAX has been the topic of several recent analyst reports. The Goldman Sachs Group cut their target price on Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating on the stock in a research note on Thursday, April 17th. JMP Securities cut their target price on Dynavax Technologies from $33.00 to $31.00 and set a "market outperform" rating on the stock in a research note on Wednesday, May 7th. Finally, Wall Street Zen cut Dynavax Technologies from a "buy" rating to a "hold" rating in a research note on Tuesday, May 6th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $24.00.

Dynavax Technologies Stock Up 2.2%

Dynavax Technologies stock traded up $0.23 during trading hours on Wednesday, hitting $10.67. 897,502 shares of the stock traded hands, compared to its average volume of 2,147,384. The firm's 50-day moving average price is $10.04 and its two-hundred day moving average price is $11.76. The company has a current ratio of 11.93, a quick ratio of 10.84 and a debt-to-equity ratio of 0.49. The company has a market cap of $1.28 billion, a PE ratio of -20.52 and a beta of 1.03. Dynavax Technologies Corporation has a one year low of $9.22 and a one year high of $14.63.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.14). The firm had revenue of $68.16 million for the quarter, compared to the consensus estimate of $70.01 million. Dynavax Technologies had a negative net margin of 20.39% and a positive return on equity of 3.59%. On average, research analysts forecast that Dynavax Technologies Corporation will post 0.32 EPS for the current year.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.